MX2017011642A - Metodos de preparacion de polinucleotidos usando composiciones salinas de cationes multivalentes. - Google Patents

Metodos de preparacion de polinucleotidos usando composiciones salinas de cationes multivalentes.

Info

Publication number
MX2017011642A
MX2017011642A MX2017011642A MX2017011642A MX2017011642A MX 2017011642 A MX2017011642 A MX 2017011642A MX 2017011642 A MX2017011642 A MX 2017011642A MX 2017011642 A MX2017011642 A MX 2017011642A MX 2017011642 A MX2017011642 A MX 2017011642A
Authority
MX
Mexico
Prior art keywords
polynucleotide
salt
multivalent cation
methods
cation salt
Prior art date
Application number
MX2017011642A
Other languages
English (en)
Inventor
H Ramiya Premchandran
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of MX2017011642A publication Critical patent/MX2017011642A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los aspectos de la descripción incluyen métodos para la preparación de un polinucleótido. En algunas modalidades, el método incluye poner en contacto una primera composición de polinucleótidos que incluye: un polinucleótido que tiene una secuencia de 7 o más subunidades nucleósido donde al menos dos de las subunidades nucleósido están unidas por un enlace entre subunidades de tiofosforamidato N3'?P5'; y reactivos y productos sintéticos no objetivo; con una sal de cationes multivalente para precipitar una primera sal de polinucleótidos que incluye al menos un contraión de cationes multivalente; y separar la sal de polinucleótidos de la primera composición de polinucleótidos en contacto para producir una segunda composición de polinucleótidos que incluye la primera sal de polinucleótidos. En determinadas modalidades, el método incluye además poner en contacto la primera sal de polinucleótidos con un soporte de cromatografía de fase inversa; y eluir a partir del soporte de cromatografía una tercera composición de polinucleótidos que incluye una segunda sal de polinucleótidos. También se proporcionan composiciones que incluyen una sal del polinucleótido que incluye al menos un contraión de cationes multivalentes.
MX2017011642A 2015-04-23 2016-04-21 Metodos de preparacion de polinucleotidos usando composiciones salinas de cationes multivalentes. MX2017011642A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562151891P 2015-04-23 2015-04-23
PCT/US2016/028657 WO2016172346A1 (en) 2015-04-23 2016-04-21 Methods of polynucleotide preparation using multivalent cation salt compositions

Publications (1)

Publication Number Publication Date
MX2017011642A true MX2017011642A (es) 2017-11-02

Family

ID=55911083

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011642A MX2017011642A (es) 2015-04-23 2016-04-21 Metodos de preparacion de polinucleotidos usando composiciones salinas de cationes multivalentes.

Country Status (36)

Country Link
US (2) US10745687B2 (es)
EP (1) EP3286203B1 (es)
JP (3) JP2018513127A (es)
KR (1) KR102401252B1 (es)
CN (2) CN113564168A (es)
AU (2) AU2016250576C1 (es)
BR (1) BR112017019627B1 (es)
CA (1) CA2978191C (es)
CL (1) CL2017002314A1 (es)
CO (1) CO2017009217A2 (es)
CY (1) CY1123197T1 (es)
DK (1) DK3286203T3 (es)
EA (1) EA035885B1 (es)
ES (1) ES2798270T3 (es)
HK (1) HK1251234A1 (es)
HR (1) HRP20201218T1 (es)
HU (1) HUE051148T2 (es)
IL (1) IL254222A0 (es)
LT (1) LT3286203T (es)
MA (2) MA42157A (es)
MD (1) MD3286203T2 (es)
ME (1) ME03811B (es)
MX (1) MX2017011642A (es)
MY (1) MY187804A (es)
PE (2) PE20221275A1 (es)
PH (1) PH12017501927A1 (es)
PT (1) PT3286203T (es)
RS (1) RS60645B1 (es)
SA (1) SA517390103B1 (es)
SG (2) SG11201707893RA (es)
SI (1) SI3286203T1 (es)
TN (1) TN2017000411A1 (es)
TW (1) TWI736532B (es)
UA (1) UA124521C2 (es)
WO (1) WO2016172346A1 (es)
ZA (1) ZA201706041B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3286203T1 (sl) 2015-04-23 2020-10-30 Geron Corporation Metode priprave polinukleotida, z uporabo sestavkov multivalentne kationske soli
WO2018111967A1 (en) 2016-12-13 2018-06-21 Modernatx, Inc. Rna affinity purification
EP3554556B1 (en) 2016-12-19 2022-03-09 Ventana Medical Systems, Inc. Peptide nucleic acid conjugates
WO2019036683A1 (en) * 2017-08-18 2019-02-21 Modernatx, Inc. ANALYTICAL METHODS BY HPLC
EP3684933A4 (en) * 2017-09-22 2021-06-23 The Regents of the University of Colorado, A Body Corporate OLIGONUCLEOTIDES THIOMORPHOLINO FOR THE TREATMENT OF MUSCLE DYSTROPHY
WO2019120635A1 (en) * 2017-12-18 2019-06-27 Ventana Medical Systems, Inc. Peptide nucleic acid conjugates

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046720A (en) 1974-01-17 1977-09-06 California Institute Of Technology Crosslinked, porous, polyacrylate beads
US4678814A (en) 1981-03-30 1987-07-07 California Institute Of Technology Polyacrolein microspheres
US4413070A (en) 1981-03-30 1983-11-01 California Institute Of Technology Polyacrolein microspheres
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
DE69120821T2 (de) 1990-08-31 1997-01-23 Univ Minnesota Polyethylenglykol-Derivate für Festphasenanwendungen
US5281701A (en) 1991-07-12 1994-01-25 Applied Biosystems, Inc. Process and compounds for RNA synthesis
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US5726297A (en) 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
AU704549B2 (en) 1994-03-18 1999-04-29 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
WO1998028442A1 (en) 1996-12-20 1998-07-02 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
US5998604A (en) 1997-09-15 1999-12-07 The Perkin-Elmer Corporation Polynucleotide purification method
US6114519A (en) 1997-10-15 2000-09-05 Isis Pharmaceuticals, Inc. Synthesis of sulfurized oligonucleotides
US6465628B1 (en) 1999-02-04 2002-10-15 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
DE60038495T2 (de) 1999-09-10 2009-04-09 Geron Corp., Menlo Park Oligonukleotid n3'-p5' thiophosphoramidate: ihre synthese und verwendung
JP2002060341A (ja) * 2000-08-21 2002-02-26 Terumo Corp 止血剤
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
AU2002245717A1 (en) 2001-03-23 2002-10-08 Geron Corporation Oligonucleotide conjugates
EP3682903A1 (en) * 2003-09-09 2020-07-22 Geron Corporation Modified oligonucleotides for telomerase inhibition
US20120329858A1 (en) 2010-08-04 2012-12-27 Geron Corporation Modified oligonucleotides for telomerase inhibition
TW200540180A (en) 2004-05-28 2005-12-16 Sankyo Co Telomerase inhibitor ena oligonucleotide
PT1778711T (pt) 2004-07-02 2017-10-19 Geron Corp Síntese de monómeros nucleosídeos 3'-amino protegidos
WO2007041201A2 (en) * 2005-10-03 2007-04-12 Applera Corporation Compositions, methods, and kits for amplifying nucleic acids
TWI442965B (zh) * 2006-11-01 2014-07-01 Biogen Idec Inc 使用低ｐＨ及二價陽離子分離生物巨分子的方法
JP5775581B2 (ja) * 2010-08-20 2015-09-09 レプリコール インコーポレーティッド オリゴヌクレオチドキレート錯体
US9106103B2 (en) 2011-09-23 2015-08-11 Eaton Corporation Unintteruptible power supply systems and methods employing on-demand energy storage
US9006630B2 (en) 2012-01-13 2015-04-14 Altasens, Inc. Quality of optically black reference pixels in CMOS iSoCs
AR091065A1 (es) 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
CN110343673B (zh) * 2012-06-14 2024-04-05 生命技术公司 用于聚合酶链式反应(pcr)的新型组合物、方法和试剂盒
UA117116C2 (uk) * 2012-12-07 2018-06-25 Джерон Корпорейшн Використання інгібітора теломерази для лікування мієлопроліферативних неоплазм
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
SI3286203T1 (sl) 2015-04-23 2020-10-30 Geron Corporation Metode priprave polinukleotida, z uporabo sestavkov multivalentne kationske soli

Also Published As

Publication number Publication date
CN107429247B (zh) 2021-08-13
PH12017501927A1 (en) 2018-03-05
RS60645B1 (sr) 2020-09-30
HUE051148T2 (hu) 2021-03-01
KR102401252B1 (ko) 2022-05-24
ZA201706041B (en) 2020-11-25
MA42157A (fr) 2018-02-28
SI3286203T1 (sl) 2020-10-30
SG10201909816PA (en) 2019-11-28
IL254222A0 (en) 2017-10-31
PT3286203T (pt) 2020-07-08
PE20171785A1 (es) 2017-12-27
US20160312227A1 (en) 2016-10-27
CN113564168A (zh) 2021-10-29
EA201791753A1 (ru) 2018-04-30
WO2016172346A1 (en) 2016-10-27
CA2978191C (en) 2022-10-04
MD3286203T2 (ro) 2020-08-31
EA035885B1 (ru) 2020-08-27
BR112017019627A2 (pt) 2018-05-15
SA517390103B1 (ar) 2021-07-14
BR112017019627B1 (pt) 2022-11-29
TW201706284A (zh) 2017-02-16
AU2016250576B2 (en) 2021-02-04
CA2978191A1 (en) 2016-10-27
TN2017000411A1 (en) 2019-01-16
NZ735042A (en) 2021-11-26
JP2021152079A (ja) 2021-09-30
SG11201707893RA (en) 2017-11-29
AU2016250576C1 (en) 2021-05-06
LT3286203T (lt) 2020-07-27
CN107429247A (zh) 2017-12-01
UA124521C2 (uk) 2021-10-05
ME03811B (me) 2021-04-20
JP2018513127A (ja) 2018-05-24
CL2017002314A1 (es) 2018-05-04
MY187804A (en) 2021-10-26
JP2022168017A (ja) 2022-11-04
US10745687B2 (en) 2020-08-18
ES2798270T3 (es) 2020-12-10
KR20170138399A (ko) 2017-12-15
US20200339975A1 (en) 2020-10-29
CY1123197T1 (el) 2021-10-29
DK3286203T3 (da) 2020-06-02
AU2016250576A1 (en) 2017-09-21
TWI736532B (zh) 2021-08-21
HK1251234A1 (zh) 2019-01-25
CO2017009217A2 (es) 2018-02-20
US11441144B2 (en) 2022-09-13
AU2021202803A1 (en) 2021-06-03
MA42569B1 (fr) 2020-08-31
EP3286203A1 (en) 2018-02-28
PE20221275A1 (es) 2022-09-01
HRP20201218T1 (hr) 2020-12-11
EP3286203B1 (en) 2020-05-06

Similar Documents

Publication Publication Date Title
PH12017501927A1 (en) Methods of polynucleotide preparation using multivalent cation salt compositions
MA40074A (fr) Composés liant ras multivalents
CL2018003136A1 (es) Proteínas de unión específica y usos de las mismas.
BR112019007288A2 (pt) proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente
CL2017003132A1 (es) Moléculas de unión a lag-3 y métodos de uso de las mismas
WO2018083087A3 (en) Binding proteins
CL2017001154A1 (es) Moléculas de unión específicas para cd73 y usos de las mismas
BR112017003582A2 (pt) anticorpos, composições e usos
BR112018000475A2 (pt) construtos de anticorpo biespecíficos que se ligam a dll3 e a cd3
BR112018010410A2 (pt) método para tratar câncer em um sujeito, composição e métodos de aumento do número de células nk e de aumento do número de uma ou mais células positivas para pd-l1
GEP20227419B (en) Pd-1-binding molecules and methods of use thereof
BR112018002824A2 (pt) anticorpo, polinucleotídeo, vetor, célula, métodos para expressar o anticorpo, para tratar uma condição associada com pd-1 e para tratar uma condição em um sujeito, kit, composição farmacêutica e uso do anticorpo
BR112016030908A2 (pt) moléculas com especificidade para cd45 e cd79
EA201791093A1 (ru) Антитела к cd47, способы и применение
BR112016014022A2 (pt) anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit
EA201400483A1 (ru) Составы собирателей и способы их применения
EA201690492A1 (ru) Проникающие в клетку конъюгаты и способы их применения
MX2023006083A (es) Npp1 para usarse en el tratamiento de calcificacion de tejidos.
BR112016030950A2 (pt) polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira.
MX2021001418A (es) Produccion de proteinas heteromultimericas usando celulas de mamifero.
WO2014145870A3 (en) Novel compositions, methods and kits for blood typing
BR112016019390A2 (pt) proteínas de fusão uti
BR112018005464A2 (pt) expressão de proteínas contendo fc
WO2015160928A3 (en) Isolated t cell receptors and methods of use therefor
AR110040A1 (es) Proteínas de unión biespecíficas